Lucas Sidéris1, Pierre Dubé, Anja Rinke. 1. Department of Surgery, Maisonneuve-Rosemont Hospital, University of Montréal, Montréal, Quebec, Canada. lucas.sideris@umontreal.ca
Abstract
BACKGROUND: For decades, somatostatin analogs (including octreotide and lanreotide) have been indicated for relief of the symptoms of flushing, diarrhea, and wheezing associated with secretory neuroendocrine tumors (NETs). Recently, it has been suggested that somatostatin analogs may provide direct and indirect antitumor effects in secretory and nonsecretory NETs in addition to symptom control in secretory NETs. METHODS: A systematic review of MEDLINE was conducted to identify studies that investigated the antitumor effects of octreotide or lanreotide for patients with NETs. Additional studies not published in the peer-reviewed literature were identified by searching online abstracts. Results. In all, 17 octreotide trials and 11 lanreotide trials that included antitumor effects were identified. Partial response rates were between 0% and 31%, and stable disease rates were between 15% and 89%. Octreotide was the only somatostatin analog for which results of a phase III, randomized, placebo-controlled clinical trial that investigated antitumor effects were published. After 6 months of treatment in this randomized phase III trial, stable disease was observed in 67% of patients (hazard ratio for time to disease progression: 0.34; 95% confidence interval: 0.20-0.59; p = .000072). CONCLUSIONS: In addition to symptom control for NETs, the data support an antitumor effect of somatostatin analogs and suggest that they may slow tumor growth. Long-acting repeatable octreotide has been shown to have an antitumor effect in a randomized phase III trial in midgut NETs, whereas results are pending in a corresponding controlled trial with lanreotide for patients with intestinal and pancreatic primary NETs.
BACKGROUND: For decades, somatostatin analogs (including octreotide and lanreotide) have been indicated for relief of the symptoms of flushing, diarrhea, and wheezing associated with secretory neuroendocrine tumors (NETs). Recently, it has been suggested that somatostatin analogs may provide direct and indirect antitumor effects in secretory and nonsecretory NETs in addition to symptom control in secretory NETs. METHODS: A systematic review of MEDLINE was conducted to identify studies that investigated the antitumor effects of octreotide or lanreotide for patients with NETs. Additional studies not published in the peer-reviewed literature were identified by searching online abstracts. Results. In all, 17 octreotide trials and 11 lanreotide trials that included antitumor effects were identified. Partial response rates were between 0% and 31%, and stable disease rates were between 15% and 89%. Octreotide was the only somatostatin analog for which results of a phase III, randomized, placebo-controlled clinical trial that investigated antitumor effects were published. After 6 months of treatment in this randomized phase III trial, stable disease was observed in 67% of patients (hazard ratio for time to disease progression: 0.34; 95% confidence interval: 0.20-0.59; p = .000072). CONCLUSIONS: In addition to symptom control for NETs, the data support an antitumor effect of somatostatin analogs and suggest that they may slow tumor growth. Long-acting repeatable octreotide has been shown to have an antitumor effect in a randomized phase III trial in midgut NETs, whereas results are pending in a corresponding controlled trial with lanreotide for patients with intestinal and pancreatic primary NETs.
Authors: M Ducreux; P Ruszniewski; J A Chayvialle; J Blumberg; D Cloarec; H Michel; J M Raymond; J L Dupas; H Gouerou; R Jian; E Genestin; P Hammel; P Rougier Journal: Am J Gastroenterol Date: 2000-11 Impact factor: 10.864
Authors: Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen Journal: Pancreas Date: 2010-08 Impact factor: 3.327
Authors: S Ricci; A Antonuzzo; L Galli; C Orlandini; M Ferdeghini; G Boni; M Roncella; F Mosca; P F Conte Journal: Am J Clin Oncol Date: 2000-08 Impact factor: 2.339
Authors: A N Wymenga; B Eriksson; P I Salmela; M B Jacobsen; E J Van Cutsem; R H Fiasse; M J Välimäki; J Renstrup; E G de Vries; K E Oberg Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: T Aparicio; M Ducreux; E Baudin; J C Sabourin; T De Baere; E Mitry; M Schlumberger; P Rougier Journal: Eur J Cancer Date: 2001-05 Impact factor: 9.162
Authors: Jennifer C Carr; Scott K Sherman; Donghong Wang; Fadi S Dahdaleh; Andrew M Bellizzi; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe Journal: Ann Surg Oncol Date: 2013-10-10 Impact factor: 5.344
Authors: David L Chan; Diego Ferone; Manuela Albertelli; Nick Pavlakis; Eva Segelov; Simron Singh Journal: Endocrine Date: 2017-07-19 Impact factor: 3.633
Authors: Zhi Rong Qian; Tingting Li; Monica Ter-Minassian; Juhong Yang; Jennifer A Chan; Lauren K Brais; Yohei Masugi; Arunthathi Thiaglingam; Nichole Brooks; Reiko Nishihara; Mireille Bonnemarie; Atsuhiro Masuda; Kentaro Inamura; Sun A Kim; Kosuke Mima; Yasutaka Sukawa; Ruoxu Dou; Xihong Lin; David C Christiani; Fabien Schmidlin; Charles S Fuchs; Umar Mahmood; Shuji Ogino; Matthew H Kulke Journal: Pancreas Date: 2016-11 Impact factor: 3.327